Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.
blackwelllrlq

Mdxhealth Licenses Epigenetic Technology To Oncgnostics Gmbh For Cervical Cancer Test - Yahoo Finance

Under the agreement, MDxHealth grants oncgnostics this link a limited, non-transferable, non-exclusive, worldwide license for its patented methylation specific PCR (MSP) technology for diagnostic applications in cervical cancer. In return, MDxHealth will receive upfront and milestone payments, and royalties on net sales. oncgnostics is one of the few diagnostic companies with a strong focus on applications in gynecological cancers, including cervical cancer. "We are pleased to work with oncgnostics, hyperlink an up-and-coming player in women's health. With three successful epigenetic products based on MDxHealth's proprietary MSP technology and biomarkers on the market; our lead product ConfirmMDx(R) for Prostate Cancer, PredictMDx(R) for read Glioblastoma (MGMT) and our licensee Exact Sciences' Cologuard(R) test for colorectal cancer screening, DNA methylation is a proven diagnostic tool for cancer detection," said Dr. Jan Groen, CEO of MDxHealth. "We are excited about oncgnostics epigenetic GynTect(R) test, which will aid in the diagnosis and treatment of women with cervical cancer." About oncgnostics GmbH Founded as a spin-off from the University Womens' Hospital Jena, oncgnostics focuses on in vitro diagnostic tests for the early and accurate detection of cancer utilizing proprietary epigenetic biomarkers.
More: http://finance.yahoo.com/news/mdxhealth-licenses-epigenetic-technology-oncgnostics-070603262.html

Don't be the product, buy the product!

Schweinderl